Companies

ARVN · Biotech

ARVINAS, INC.

SEC company filings

Reported cash

USD 88,000,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

Next verified event · Clinical readout window

ARV-393 · additional monotherapy data · mid 2027

B- and T-cell lymphomas

Phase 1

NCT06393738

Announced Nov 3, 2026 · Announced window

Official announcement
Source wording

•Share additional monotherapy data from the ongoing Phase 1 dose escalation clinical trial in patients with B- and T-cell lymphomas (mid-2027).

Clinical readout window

ARV-393 · combination data · mid 2027

DLBCL

Phase 1

NCT06393738

Announced Nov 3, 2026 · Announced window

Official announcement
Source wording

•Share initial data from the combination cohort with glofitamab in patients with DLBCL in the ongoing Phase 1 clinical trial (mid-2027).

Clinical readout window

ARV-6723 · clinical data · H2 2027

Announced Nov 3, 2026 · Announced window

Official announcement
Source wording

•Present initial monotherapy data from the Phase 1 clinical trial (2H 2027).

Drug pipeline

9 programs · 5 verified studies

Anastrozole

Phase

Phase2

Study status

Completed
View details

ARVINAS, INC.

IndicationBreast Cancer

Actual study completion2024-07-25

ARV-110

Phase

Phase1 / Phase2

Study status

Completed
View details

ARVINAS, INC.

IndicationProstate Cancer Metastatic

Actual study completion2025-01-27

ARV-393

Phase

Phase1

Study status

Recruiting
View details

ARVINAS, INC.

IndicationRelapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Estimated study completion2028-03

Announced catalyst timingmid 2027

Announced catalyst timingmid 2027

ARV-471

Phase

Phase2

Study status

Completed
View details

ARVINAS, INC.

IndicationBreast Cancer

Actual study completion2024-07-25

ARV-6723

Phase

Phase1 / Phase2

Study status

Recruiting
View details

ARVINAS, INC.

IndicationAdvanced Solid Tumor

Estimated study completion2032-03-31

Announced catalyst timingH2 2027

ARV-806

Phase

Phase1 / Phase2

Study status

Active not recruiting
View details

ARVINAS, INC.

IndicationKRAS G12D Mutation; Advanced Solid Cancer

Estimated study completion2026-11-30

Glofitamab

Phase

Phase1

Study status

Recruiting
View details

ARVINAS, INC.

IndicationRelapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Estimated study completion2028-03

Announced catalyst timingmid 2027

Announced catalyst timingmid 2027

Pembrolizumab

Phase

Phase1 / Phase2

Study status

Recruiting
View details

ARVINAS, INC.

IndicationAdvanced Solid Tumor

Estimated study completion2032-03-31

Announced catalyst timingH2 2027

SOC

Phase

Phase1 / Phase2

Study status

Recruiting
View details

ARVINAS, INC.

IndicationAdvanced Solid Tumor

Estimated study completion2032-03-31

Announced catalyst timingH2 2027

22 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.